Fig 1.
This is the workflow displaying inclusion and exclusion criteria.
GvH: Graft versus Host, FSGS: focal segmental glomerulosclerosis, IgA: IgA nephropathy, DM: diabetes mellitus, HTN: hypertension, GN-IC: immune complex glomerulonephritis.
Table 1.
These are the patients’ demographics.
Continuous data are presented as median (range). UPCR: urine protein creatinine ratio, RAS: Renin Angiotensin System.
Fig 2.
These are antibody titers (RU/ml) with IQR and range, shown on Log10 scale.
Fig 3.
It shows the sensitivity and specificity of the serum PLA2R antibody test in our study. Area under curve: 0.943, p<0.0001.
Table 2.
This is the 2*2 diagnostic accuracy table.
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the anti-PLA2R ELISA with antibody titer ≥20 RU/ml interpreted as positive.
Table 3.
Sensitivity, specificity and Youden’s index of the anti-PLA2R test in diagnosing PMN in this study, over varying cut-off thresholds.